365 related articles for article (PubMed ID: 21972245)
21. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
22. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
[TBL] [Abstract][Full Text] [Related]
23. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
24. Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes.
Martin I; Abalde-Atristain L; Kim JW; Dawson TM; Dawson VL
Fly (Austin); 2014; 8(3):165-9. PubMed ID: 25483009
[TBL] [Abstract][Full Text] [Related]
25. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
[TBL] [Abstract][Full Text] [Related]
27. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.
Trancikova A; Mamais A; Webber PJ; Stafa K; Tsika E; Glauser L; West AB; Bandopadhyay R; Moore DJ
PLoS One; 2012; 7(10):e47784. PubMed ID: 23082216
[TBL] [Abstract][Full Text] [Related]
29. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
[TBL] [Abstract][Full Text] [Related]
30. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
[TBL] [Abstract][Full Text] [Related]
32. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
33. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
Gillardon F
J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
[TBL] [Abstract][Full Text] [Related]
34. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
36. Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study.
Ning B; Guo G; Gu C; Xu J; Bibic A; He X; Liu H; Chen L; Wei Z; Duan W; Liu P; Lu H; van Zijl PCM; Ross CA; Smith W; Hua J
Neurodegener Dis; 2020; 20(2-3):65-72. PubMed ID: 33152738
[TBL] [Abstract][Full Text] [Related]
37. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
Kelly K; Wang S; Boddu R; Liu Z; Moukha-Chafiq O; Augelli-Szafran C; West AB
Exp Neurol; 2018 Nov; 309():1-13. PubMed ID: 30048714
[TBL] [Abstract][Full Text] [Related]
38. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
39. Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.
Lin CH; Lin HY; Ho EP; Ke YC; Cheng MF; Shiue CY; Wu CH; Liao PH; Hsu AY; Chu LA; Liu YD; Lin YH; Tai YC; Shun CT; Chiu HM; Wu MS
Mov Disord; 2022 Apr; 37(4):745-757. PubMed ID: 34918781
[TBL] [Abstract][Full Text] [Related]
40. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
